No mutations in human CDK6 have been identified, although enhanced CDK6 expression has been documented in lymphoma and leukemia (Chilosi et al., 1998, Lien et al., 2000, Nagel et al., 2008, Schwartz et al., 2006), and several reports have documented chromosomal translocations in patients suffering from B-lymphoid malignancies involving CDK6. In these patients, the aberrant and increased expression of CDK6 has been proposed to be the cause and/or driving force for the disease (Brito-Babapulle et al., 2002, Chen et al., 2009, Hayette et al., 2003, Parker et al., 2012). Here, CDK6 is linked to lymphoma.